June 13, 2019

Company Name: HEALIOS K.K.
Representative: Hardy TS Kagimoto,
Chairman & CEO
(TSE Mothers Code: 4593)

Appointment of Executive Officer Chief Financial Officer

HEALIOS K.K. ("Healios") today announces that it is decided to appoint Mr. Richard P. Kincaid as executive officer and Chief Financial Officer (CFO) of Healios from July 16, 2019. Originally Mr. Kincaid was appointed as an external director at the annual shareholders' meeting held on March 2019, but by this change he will become an internal director of Healios.

Mr. Kincaid started his career at Goldman Sachs in Japan, and then in 2004 he established a hedge fund management firm based in Hong Kong, Nezu Asia Capital Management, where he has been a partner for over 15 years and holds the role of president.

Hardy TS Kagimoto, MD, Chairman and CEO of Healios commented as below:

"I am pleased to be able to appoint Mr. Kincaid as our executive officer CFO. I am expecting that he will be able to make a significant contribution to our growth as a global leader in regenerative/cellular medicine, taking advantage of his diverse experience in investment, risk management, fund raising through the capital market and of business management as a fund manager.
Following our mission, 'To foster a Life Explosion that enriches the lives of people around the world', we will strengthen our leadership and work even harder to deliver innovative treatments to patients around the world."